![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » New York Reviewing Vertex’s Drug Over Medicaid Spending Cap Concerns
New York Reviewing Vertex’s Drug Over Medicaid Spending Cap Concerns
![100Bills_flatmoney.gif](https://www.fdanews.com/ext/resources/test/Drug-Images3/100Bills_flatmoney.gif?t=1578960048&width=430)
April 11, 2018
A New York drug review board will convene April 26 to review Vertex’s cystic fibrosis treatment Orkambi (lumacaftor/ivacaftor), which the state identified as contributing to overages on the state’s Medicaid drug spending cap.
The Orkambi review is the first since the state passed a law last year putting a cap on Medicaid spending.
The combination drug, approved by the FDA in 2015, costs $259,000 per patient per year.
Upcoming Events
-
21Oct